XCUR — EXICURE, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1698530 ·
Last close
$1.60
Market Cap
$10.20M
52W High
$3.55
52W Low
$1.43
ADV30
810,530
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,603,000 | -1,828,000 | 12,755,000 | 2,604,000 | 10,657,000 |
| Dec 2025 | 0 | — | -2,256,000 | -2,898,000 | 14,041,000 | 3,746,000 | 10,115,000 |
| Sep 2025 | 0 | — | -2,387,000 | -2,437,000 | 15,267,000 | 4,438,000 | 8,340,000 |
| Jun 2025 | 0 | — | -2,449,000 | -2,621,000 | 18,738,000 | 7,858,000 | 9,875,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,099,000
Investing CF
$283,000
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.60
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-206,038,000
Inventory
—
Receivables
$60,000
ST Investments
—
EBIT TTM
$-10,020,000
Pretax Income TTM
$-10,418,000
Interest Exp TTM
$13,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,117,000 | -4,946,000 | 14,041,000 | 10,115,000 | — | -8,555,000 |
| Dec 2024 | 500,000 | -4,949,000 | -9,701,000 | 15,056,000 | 8,284,000 | — | -2,910,000 |
| Dec 2023 | 0 | -13,138,000 | -16,914,000 | 11,580,000 | 8,549,000 | — | -10,357,000 |
| Dec 2022 | 28,826,000 | -1,831,000 | -2,582,000 | 23,328,000 | 8,406,000 | — | -35,658,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-1,661,000
NetIncome TTM
$-35,038,000
OpCashFlow TTM
$0
Assets (Latest)
$15,056,000
Forward EPS
$-0.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BFRG | BullFrog AI Holdings, Inc. | $10.29M | $0.56 | — |
| VTGN | Vistagen Therapeutics, Inc. | $9.85M | $0.24 | — |
| GTBP | GT Biopharma, Inc. | $10.60M | $0.29 | — |
| TOVX | Theriva Biologics, Inc. | $9.64M | $0.21 | — |
| GDTC | CytoMed Therapeutics Ltd | $11.00M | $0.93 | — |
News headlines (Yahoo Finance, 1h cache)
Exicure Announces Board and Committee Changes
2026-06-30 12:40 · Yahoo
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
2026-06-10 20:01 · Yahoo
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
2026-06-01 20:00 · Yahoo
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
2026-04-22 23:54 · Yahoo
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
2026-04-02 20:01 · Yahoo
Exicure, Inc. Reports Full Year 2025 Financial Results
2026-03-25 20:18 · Yahoo
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
2026-02-05 12:00 · Yahoo
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
2026-01-21 12:00 · Yahoo
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
2025-12-08 21:30 · Yahoo
Exicure, Inc. Reports Third Quarter 2025 Financial Results
2025-11-07 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.